Torrent Pharmaceuticals Limited (TORNTPHARM)
Press Release
Press Release - Q2 FY27
- Revenue Rs 4,979 Cr +51% y-y; Op. EBITDA Rs 1,666 Cr +54% y-y; Op. EBITDA margin 33.5%; PAT Rs 534 Cr
- India base business revenues up 20%, outperforming IPM growth of 12%
- Brazil revenues up 38%, constant currency +20%, with 53 products under ANVISA review
- US revenues up 24%, constant currency +13%, driven by new launches
- Germany revenues down 7%, impacted by supply disruptions and tender losses
- JB business revenues down 7% internationally due to post-merger integration impact
- H1 FY27 consolidated revenues Rs 9,900 Cr +53%, Op. EBITDA Rs 3,330 Cr +57%, PAT Rs 1,100 Cr -3%
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TORNTPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TORNTPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Torrent Pharmaceuticals Limited
Important.
The summary above is generated automatically from Torrent Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.